{rfName}
Cl

Indexed in

License and use

Citations

9

Altmetrics

Analysis of institutional authors

Castelo, BeatrizAuthorZamora, PilarAuthorFeliu JAuthorFeliu, JaimeAuthorEspinosa, EnriqueCorresponding Author

Share

July 21, 2024
Publications
>
Review
Hybrid Gold

Classification of anticancer drugs: an update with FDA- and EMA-approved drugs

Publicated to:CANCER AND METASTASIS REVIEWS. - 2024-07-05 (), DOI: 10.1007/s10555-024-10188-5

Authors: Ostios-Garcia L; Pérez DM; Castelo B; Herradón NH; Zamora P; Feliu J; Espinosa E

Affiliations

Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain - Author
Univ Autonoma Madrid, Hosp Univ La Paz, Sch Med, Dept Med Oncol,Madrid CIBERONC, Madrid, Spain - Author

Abstract

Anticancer systemic therapy comprises a complex and growing group of drugs. Some of the new agents with novel mechanisms of action that have appeared are difficult to fit in the groups of classical chemotherapy, hormones, tyrosine-kinase inhibitors, and monoclonal antibodies. We propose a classification based on two levels of information: the site of action and the mechanism of action. Regarding the former, drugs can exert their action in the tumor cell, the tumor vasculature, the immune system, or the endocrine system. The mechanism of action refers to the molecular target.

Keywords

American societyAntineoplastic agentsBlockadCancerChemotherapyClassificationImmunotherapImmunotherapyLenalidomideMechanismsMonoclonal antibodiesPomalidomideProliferationResistanceThalidomideTherapyTyrosine-kinase inhibitors

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal CANCER AND METASTASIS REVIEWS due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 37/322, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-16:

  • Scopus: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 60 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
  • Assignment of a Handle/URN as an identifier within the deposit in the Institutional Repository: https://repositorio.uam.es/handle/10486/713982

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (ESPINOSA ARRANZ, ENRIQUE).

the author responsible for correspondence tasks has been ESPINOSA ARRANZ, ENRIQUE.